We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+0.5%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$9.7B
AUM Growth
-$152M
Cap. Flow
+$293M
Cap. Flow %
3.03%
Top 10 Hldgs %
29.73%
Holding
234
New
14
Increased
60
Reduced
64
Closed
43

Top Buys

Rank Stock Value
1
CDNA icon
CareDx
CDNA
+$74.9M
2
ABT icon
Abbott
ABT
+$45.9M
3
MOH icon
Molina Healthcare
MOH
+$43.5M
4
DHR icon
Danaher
DHR
+$42M
5
MDT icon
Medtronic
MDT
+$38M

Top Sells

Rank Stock Value
1
HRC
HILL-ROM HOLDINGS, INC.
HRC
+$63.1M
2
BAX icon
Baxter International
BAX
+$38.1M
3
CNC icon
Centene
CNC
+$36.2M
4
HOLX
Hologic
HOLX
+$21.4M
5
DXCM icon
DexCom
DXCM
+$16.5M

Sector Composition

Rank Sector Weight
1 Healthcare 97.85%
2 Technology 0.8%
3 Industrials 0.75%
4 Communication Services 0.02%
5 Energy 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRNA icon
1
Moderna
MRNA
$24.5B
$434M 4.47%
1,709,249
-18,100
-1% -$5.29M
VRTX icon
2
Vertex Pharmaceuticals
VRTX
$123B
$393M 4.06%
1,791,761
+30,145
+2% +$5.86M
ARGX icon
3
argenx
ARGX
$53.8B
$349M 3.6%
997,038
+13,100
+1% +$3.98M
IONS icon
4
Ionis Pharmaceuticals
IONS
$8.99B
$315M 3.25%
10,355,123
+1,007,197
+11% +$31.7M
NBIX icon
5
Neurocrine Biosciences
NBIX
$17.2B
$271M 2.79%
3,180,551
+176,500
+6% +$16.2M
ABT icon
6
Abbott
ABT
$175B
$246M 2.53%
1,745,801
+358,302
+26% +$45.9M
ALNY icon
7
Alnylam Pharmaceuticals
ALNY
$35.7B
$226M 2.33%
1,335,140
-73,278
-5% -$13.6M
FATE icon
8
Fate Therapeutics
FATE
$324M
$221M 2.28%
3,775,736
+537,700
+17% +$30.5M
INCY icon
9
Incyte
INCY
$23.4B
$217M 2.24%
2,957,000
– –
ELV icon
10
Elevance Health
ELV
$80.9B
$211M 2.18%
455,294
-19,916
-4% -$8.38M
ISRG icon
11
Intuitive Surgical
ISRG
$122B
$210M 2.16%
584,463
-26,322
-4% -$9.06M
DHR icon
12
Danaher
DHR
$144B
$195M 2.01%
667,550
+152,416
+30% +$42M
ITCI
13
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$190M 1.96%
3,628,919
-145,000
-4% -$6.09M
ARVN icon
14
Arvinas
ARVN
$517M
$183M 1.89%
2,233,403
-8,000
-0.4% -$651K
UNH icon
15
UnitedHealth
UNH
$387B
$157M 1.62%
312,281
-25,701
-8% -$11.6M
AGIO icon
16
Agios Pharmaceuticals
AGIO
$2.36B
$143M 1.47%
4,349,292
+7,300
+0.2% +$294K
TNDM icon
17
Tandem Diabetes Care
TNDM
$1.17B
$143M 1.47%
949,257
-85,262
-8% -$11.5M
HUM icon
18
Humana
HUM
$48B
$141M 1.45%
303,697
-9,065
-3% -$4.01M
MGNX icon
19
MacroGenics
MGNX
$285M
$137M 1.42%
8,560,462
+15,865
+0.2% +$299K
SAGE
20
DELISTED
Sage Therapeutics
SAGE
$137M 1.42%
3,228,004
+19,000
+0.6% +$796K
DXCM icon
21
DexCom
DXCM
$29.6B
$126M 1.3%
940,612
-114,744
-11% -$16.5M
RLAY icon
22
Relay Therapeutics
RLAY
$4.34B
$126M 1.3%
4,105,962
+350,000
+9% +$11.1M
BIIB icon
23
Biogen
BIIB
$30.4B
$126M 1.3%
525,000
-2,000
-0.4% -$514K
BSX icon
24
Boston Scientific
BSX
$65.4B
$126M 1.3%
2,964,031
-3,096
-0.1% -$130K
EW icon
25
Edwards Lifesciences
EW
$49.4B
$119M 1.23%
921,185
+51,234
+6% +$5.98M
1
2 3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2021 Portfolio in Review

As of Q4 2021, Bellevue Group held 234 positions worth $9.7B, down 1.5% from $9.85B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Bellevue Group deployed $293M of net new capital in Q4 2021, opening 14 new positions and adding to 60 existing holdings. Its largest new stake was AstraZeneca: 29,500 shares worth $3.44M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Baxter International, an estimated $38.1M trimmed.

  • Bellevue Group's largest Q4 2021 buy was AstraZeneca: 29,500 shares worth $3.44M.
  • Bellevue Group added most to CareDx in Q4 2021, an estimated $74.9M increase.
  • Bellevue Group's biggest Q4 2021 reduction was Baxter International, cutting an estimated $38.1M.
  • Bellevue Group fully exited HILL-ROM HOLDINGS, INC. in Q4 2021, selling an estimated $63.1M.
  • Bellevue Group's ten largest holdings make up 30% of its $9.7B portfolio in Q4 2021.
  • Bellevue Group opened 14 new positions and closed 43 in Q4 2021.
  • Bellevue Group's portfolio value fell 1.5% quarter-over-quarter to $9.7B.

Based on Bellevue Group's 13F filing for Q4 2021, filed 10 Feb 2022.